Normal Saline for Parenteral Use Market
Number of pages: 100 | Report Format: PDF | Published date: April 05, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.28 billion |
|
Revenue Forecast in 2031 |
US$ 5.32 billion |
|
CAGR |
5.5% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global normal saline for the parenteral use market was valued at US$ 3.28 billion in 2022 and is expected to register a revenue CAGR of 5.5% to reach US$ 5.32 billion by 2031.
Normal Saline for Parenteral Use Market Fundamentals
Normal saline is a key component of intravenous solutions used in the therapeutic environment. It is a crystalloid substance that is given intravenously. Its recommendations include hydration and electrolyte changes in both adult and pediatric groups. It is available in various strengths, including 0.9% and 0.45%. The FDA has authorized the following main indications for using normal saline infusion: Replacement of extracellular fluid (e.g., dehydration, hypovolemia, hemorrhage, sepsis), treatment of metabolic alkalosis when fluid depletion is present, and mild sodium deficiency. It is also used as a priming solution for different treatments (such as hemodialysis) and to begin and end blood transfusions. Sodium chloride infusions are also used as pharmaceutic auxiliaries and diluents to infuse the right medication ingredients.
The primary reason for using crystalloid fluids in people is because they are isotonic compared to serum plasma. There is less of an osmotic impact when compared to other kinds of fluids (e.g., hypertonic, hypotonic). Electrolytes (sodium and chloride atoms) separate in solution in normal saltwater. Sodium ions are the primary constituents of extracellular fluid, playing an important role in fluid and electrolyte diffusion. Chloride is another essential ion that acts as a buffering agent in the airways and organs. In this case, chloride aids in coupling oxygen and carbon dioxide to hemoglobin. The kidneys mainly control these ions, which regulate balance through absorption and excretion within the tubules. The flexible container is made of non-latex plastic materials specifically intended for various parenteral medications, including those that require distribution in polyolefin or polypropylene vessels.
Normal saline management necessitates assessment alongside the patient's clinical state. Clinicians, including nurses, must recognize when to use this IV fluid and when there is a risk of unfavorable side effects from overhydration. Because of the well-known adverse effects of normal saline, there have been worries about its use in severely sick patients. As a result, nursing reporting surprising results to the clinical staff is critical. Hyperchloremia was linked to a higher risk of death.
The increasing prevalence of diarrhea around the globe will be a major development driver for the market for normal saline for parenteral use. Diarrhea depletes the body's water and nutrient stores, putting the patient at risk of dehydration. Children whose bodies cannot withstand the effects of such illnesses may suffer worse outcomes. Parenteral administration of normal saline is the fastest and most efficient method to give a diarrheal patient the fluids they need to remain alive.
The key market trends for normal saline for parenteral use are robust investments in new advancements. Applications for normal saline are expanding due to the development of specialized formulations for niche markets. Additionally, increasing regulatory authority approvals are enhancing the product's sales.
[64564]
Normal Saline for Parenteral Use Market Dynamics
Normal saline is widely used in clinics to treat various diseases, including exhaustion, electrolyte imbalance, wound dressing, sepsis, bleeding, etc. However, fluid and electrolyte imbalances are among the most prevalent derangements in preterm and severely ill infants. The increasing frequency of neonatal sepsis is expected to boost sales of normal saline for parenteral use. According to the Victorian Agency for Health Information, neonatal sepsis affects 1 to 8 out of every 1,000 live newborns in Victoria, Australia. Neonatal sepsis affects 1 to 50 out of every 1,000 live newborns worldwide annually.
Furthermore, rising government guidance and suggestions for using 0.9% sodium chloride and fluid resuscitation in critical situations are expected to boost the market significantly. The Surviving Sepsis Campaign (SSC), a collaboration between the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM), recommends the use of crystalloid fluids for resuscitation during septic shock, which hospitals and academic associations widely adopt. Furthermore, 0.9% NaCl is one of the most frequently used crystalloid fluids, driving market revenue development.
Intravenous saline products, used to hydrate and administer medicines to patients hospitalized during flu season, are in high demand. Flu seasons with H3N2 as the prevalent type of the Influenza A virus, as opposed to H1N1, result in more serious complications and a significant rise in flu-related hospitalizations. The European Union's worst influenza season is expected to result in up to 50 million cases and 70,000 fatalities. During 2018-2019, 35.52 million influenza infection cases were recorded in the United States, leading to 490,561 hospitalizations. A prolonged flu season, especially in the United States, raises the demand for normal saline for parenteral use.
Cancer therapy frequently causes dehydration. Other adverse effects of chemotherapy and radiation treatment, such as fevers, vomiting, diarrhea, or excessive urination, can induce dehydration. Because of the higher fluid requirements, these therapies may necessitate IV hydration. Dehydration can also be caused by extreme heat, sweating, insufficient water, adverse drug effects, or cancer.
Furthermore, localized treatments such as surgery, radiation therapy, cryotherapy, heat or chemical ablation, and systemic medicines eradicate cancer. Following the surgery, intravenous solutions become essential to maintaining fluid balance.
As the number of medical patients in ICUs and NICUs rises, so does the demand for normal saline for parenteral use. During their medical visit, the bulk of in-patients are given saline treatment. According to the NHS, over 5 million emergency hospital stays yearly, with the vast bulk of patients receiving intravenous fluid treatment. According to the Admits and Transitions Optimization Program, more than 500,000 hospital admissions in the United States are for dehydration yearly. As a result, rising hospital admissions and a rise in the number of surgeries are expected to drive market revenue growth.
Furthermore, according to the Gastrointestinal Society, approximately 13-20% of Canadians will have irritable bowel syndrome by December 2020. In such instances, total parenteral nutrition treatment was noted as the main adjunctive therapy. According to GLOBOCAN 2020, the projected number of new brain or nervous system cancer cases in the United States in 2020 was 24,500, and it is expected to hit 30,200 by 2040. This factor is expected to boost the availability of IV solutions to hospitals.
Normal Saline for Parenteral Use Market Ecosystem
The global normal saline for the parenteral use market is analyzed by type, application, and region from the following perspectives.
Normal Saline for Parenteral Use Market by Type
[64545]
Based on type, the global normal saline for parenteral use market is segmented into plastic bottles, glass bottles, and flexible bags.
Plastic Bottles are expected to dominate the market during the forecast period. The main reasons for the revenue growth of this segment are a growing preference for plastic bottles over the glass to avoid damage during delivery and increased strategic partnerships for IV fluids. Glass bottles, as opposed to plastic receptacles, do not react with the solution kept inside them. This, combined with the rising frequency of exhaustion and the growing number of NICUs, is expected to intensify the market's revenue growth.
Normal Saline for Parenteral Use Market by Application
Based on application, the global normal saline for parenteral use market is segmented into intravascular injection, intravenous injection, and others.
The intravenous segment made for the largest revenue share of the market. The most favored delivery method for normal saline is intravenous injection, which is the main cause of the segment's dominance. Aside from that, the increasing frequency of vomiting, diarrhea, and food poisoning is expected to fuel the development of the intravenous segment. Because it is less intrusive, the intramuscular method is less unpleasant than the intravenous route. This is expected to fuel the segment's development.
Normal Saline for Parenteral Use Market by Region
Based on region, the global normal saline for parenteral use market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America will likely dominate the market with the largest revenue share during the forecast period. The strategic presence of important companies and the increasing uptake of 0.9% NaCl are factors attributable to the region's leading share. According to the FDA database, even two years after Hurricane Maria, hospitals in the United States are running out of saline treatments. The scarcity of ordinary saline allowed manufacturers to increase their manufacturing capabilities. This overall results in boosting the market revenue growth in North America.
Europe accounts for lucrative revenue growth in the normal saline for parenteral use market share. It is expected to maintain its share during the forecast period, owing to the presence of a large patient population, a strong presence of key players, ease of drug availability, a well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, a higher number of research, development, and innovation activities, and higher adoption of advanced therapeutics. However, Asia-Pacific is anticipated to develop at the fastest revenue CAGR due to increased cancer-affected people and cancer consciousness. The Asia Pacific market is expected to develop mainly due to increased hospital admissions, a growing geriatric population, and an increasing patient population. According to the Asia Pacific Sepsis Alliance, the projected national sepsis prevalence in this area varies from 120 to 1,600 per 100,000, expected to drive market development in Asia Pacific.
Competitive Landscape of the Global Normal Saline for Parenteral Use Market
Manufacturers such as ICU Medical, Fresenius Kabi AG, SSY Group Limited, and others focus on R&D and strategic collaborations to strengthen their market position. This is expected to intensify market competition. Some of the prominent market players operating in the global market include:
Strategic Development in Normal Saline for Parenteral Use Market
North America is the key growth region in the global normal saline for the parenteral use market.
The expected size of normal saline for the parenteral use market in 2031 will be 5.32 billion.
During the forecast period, the revenue CAGR of the normal saline for the parenteral use market will be 5.5%.
Some prominent market players include Pharmally International Holding Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kelun Grou, and others.
The intravenous injection segment led the global normal saline for parenteral use market.
*Insights on financial performance are subject to the availability of information in the public domain